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Summary 
Lymphocytes continuously migrate throughout the body in search of antigens. Virgin lymphocytes 
recirculate freely between the blood and different  lymphatic organs,  whereas  immunoblasts 
extravasate preferentially into sites similar to those where they initially responded  to antigen. 
Tissue-specific extravasation of lymphocytes is largely controlled by distinct lymphocyte surface 
receptors that mediate lymphocyte binding to high endothelial venules (HEV). In the present 
study, the molecular mechanisms determining the specificity of human mucosal (lamina propria) 
lymphocyte binding  to  different  endothelial  recognition  systems were  analyzed.  Mucosal 
immunoblasts adhered  five times  better than  small mucosal  lymphocytes  to  mucosal  HEV. 
Importantly, mucosal immunoblasts also bound to synovial HEV almost as efficiently as to mucosal 
HEV, but they did not adhere to peripheral lymph node HEV. To study the impact of different 
homing-associated molecules in this dual endothelial binding, we used a gut-derived T cell line 
and freshly isolated mucosal immunoblasts.  Both cell types expressed integrins oe4, 31, B7, and 
lymphocyte function associated antigen 1 (LFA-1), and were CD44 positive, but practically L- 
selectin negative. Binding of mucosal immunoblasts to mucosal HEV was almost completely 
abolished by pretreatment with anti-/~7 monodonal antibodies, but it was independent of oe4/B1 
function. In contrast, ot4//$1 partially mediated immunoblast adherence to synovial HEV, whereas 
cr4/~7 had only a minor role in adherence of blasts at this site. CD44 and LFA-1 contributed 
to HEV-binding both in mucosa and synovium.  Taken together, this  is the first report that 
demonstrates  a critical role for ot4//~7 in the binding of gut lymphocytes  to mucosal venules 
in humans. Moreover, a hitherto unknown interaction between mucosal effector cells and synovial 
endothelial cells was shown to be only partially mediated by the currently known homing receptors. 
The dual endothelial binding capacity of mucosal blasts may help to explain the pathogenesis 
of reactive arthritis not uncommonly associated with inflammatory and infectious bowel diseases. 
T  mphocyte migration is an essential component of an effec- 
.l.a  tive immune defense system allowing each lymphocyte 
with a unique antigen receptor to travel throughout the body 
to seek for specific stimulus (1). Virgin lymphocytes recircu- 
late continuously from one anatomically distinct lymphatic 
organ to another via the lymph and blood. When a lympho- 
cyte encounters its specific  antigen in a suitable microenviron- 
ment it halts and starts to proliferate and differentiate. Fi- 
nally, a mature immunoblast leaves the regional lymphatic 
tissue via lymphatics and enters the circulation.  The migra- 
tory capacity of this effector cell has changed dramatically. 
It no longer recirculates between different lymphatic organs, 
but instead, specifically extravasates into sites similar to that 
where it initially became activated (1). For example, a naive 
lymphocyte that responds to an intestinal antigen at mucosa- 
associated lymphatic tissues differentiates in Peyer's patches. 
Thereafter, the antigen-activated  immunoblasts enter the blood 
circulation  via the lymphatic system and specifically home 
back to the mucosal sites (1, 2). In humans, at least four func- 
tionally distinct endothelial binding specificities have been 
defined that direct lymphocyte trafficking to gut-associated 
lymphatic tissues, inflamed synovia, peripheral lymph nodes, 
and skin (3-5). 
When lymphocytes leave the blood, they first bind to the 
endothelial lining of vessels and then transmigrate between 
the endothelial cells into the underlying tissue. Most lyre- 
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postcapillary venules that are called high endothelial venules 
(HEV) 1 because of their characteristic morphological appear- 
ance (6). Several lymphocyte surface receptors mediate lym- 
phocyte-endothelial cell interactions by binding to their ligands 
on HEV (7-10).  Integrins are heterodimeric molecules that 
contain one ot chain noncovalently associated with a/3 chain 
(11). Integrin c~4 subunit can associate with two distinct B 
chains, B1 and/~7, in mouse, c~4/B7 heterodimer (formerly 
called LPAM-1) is the principal homing receptor that mediates 
tissue-specific  binding  of lymphocytes to  venules  in  gut- 
associated lymphatic tissues by interacting with endothelial 
mucosal addressin  cell adhesion molecule 1 (MAdCAM-1) 
(12-16). The other c~4 containing lymphocyte  integrin, ol4/~1, 
does not bind to MAdCAM-1, but it can recognize vascular 
cell adhesion molecule 1 (VCAM-1)  which is an inducible 
endothelial adhesion molecule (16-18). Other known tissue- 
selective homing receptors  are L-sdectin which guides lym- 
phocyte trafficking to peripheral lymph nodes (19, 20), and 
cutaneous lymphocyte antigen (CLA) which supports lym- 
phocyte binding to vessels in inflamed skin (21). Other lym- 
phocyte homing-associated molecules, like CD44 (22)  and 
LFA-1  (CDlla/CD18;  23) are important for lymphocyte- 
endothelial cell interactions (24-26), but they mainly func- 
tion in a nontissue-specific  manner. 
Lymphocyte recirculation pathways have been extensively 
studied in animal models. In those studies it has been shown 
that an in vitro frozen section assay predicts  very well the 
actual in vivo homing capacity of  cells (27). In humans, there 
is only a limited amount of information available on the en- 
dothdial binding of mucosal lymphocytes. We have earlier 
shown that small lymphocytes  isolated from the lamina propria 
of gut bind to HEV in both mucosa and peripheral lymph 
nodes. In contrast, mucosal immunoblasts do not adhere to 
peripheral  lymph node HEV at all, although they bind ex- 
tremely well to mucosal HEV (28). However, in humans es- 
sentially nothing is known about the molecular mechanisms 
that mediate the interactions between mucosal lymphocytes 
and vascular endothdium. We also wanted to analyze binding 
of mucosal cells to synovial HEV, since several dinically im- 
portant infectious and inflammatory bowel diseases are not 
uncommonly followed by reactive arthritis (29, 30), and we 
reasoned that capacity of mucosal effector calls to home into 
joints could be a connection between the two manifestations 
of these diseases. Therefore, in the present work we isolated 
lamina propria lymphocytes (LPL) from human bowel and 
studied their endothelial cell recognition specificities.  We found 
that mucosal immunoblasts were able to bind almost equally 
well to both mucosal and synovial HEV. When the function 
of each known homing-associated molecule was studied in- 
dividually, it was evident that immunoblasts used a distinct 
1Abbreviations  used  in  this paper: oriEL, el-chain of  intraepithelial 
lymphocyte  integrin;  HEV, high  endothelial  venules;  LPL,  lamina  propria 
lymphocytes;  MAdCAM-1, raucosal  addressin  cell adhesion  molecule 1; 
RAR, relative  adherence ratio; VCAM-1, vascular  cell adhesion  molecule 
1; VLA-4, very  late activation antigen 4. 
set of homing receptors for binding to mucosal and synovial 
HEV. 
Materials and Methods 
Isolation of LPLs.  11 normal gut specimens  were obtained from 
patients who were operated on for premalignant or malignant gut 
lesions (polyps and adenocarcinomas) or for reconstructive ab- 
dominal surgery. The tissue pieces used in these studies were taken 
from the macroscopically  and microscopically  normal area of the 
removed tissue. LPL were from colon in 3/11 samples, from small 
bowel (ileum) in 2/11, and in the rest (6/11), both small and large 
bowel LPL were pooled to provide suf~cient number of cells. We 
have shown earlier that no evident  differences  exist  in the endothelial 
cell binding properties of LPL isolated from small and large bowel 
(31). LPL were isolated  essentially  as previously  described (28, 32). 
In brief, mucosa of the gut was dissected free, and epithelial cells 
were detached by treatment with Ca  2+ and Mg  a+ free HBSS con- 
taining 5 mM EDTA. After washings, LPL were released from the 
remaining tissue pieces  by an overnight incubation in RPMI 1640, 
10% AB-serum, and 20 U/ml coUagenase  type II (from Clostridium 
histolyticum;  Sigma Chemical Co., St. Louis, MO). Mononudear 
cells were collected using Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden) gradient centrifugation. Finally, macrophages were re- 
moved from the mononuclear cell population by allowing the cells 
to adhere to plastic for 2 h at 37~  in the presence of serum. The 
nonadherent  lymphocytes  were collected  and used  for further studies. 
Isolated cells were >/98% lymphocytes as judged by leukocyte 
markers. PBL were isolated from venous blood of healthy adults 
by Ficoll-Hypaque. All cell and tissue sampling protocols used in 
this study were approved by institutional review boards. 
Mucosal T  Cell Lines.  IL-2-dependent T ceU lines were estab- 
lished as described earlier (33). Briefly,  isolated  LPL were cultured 
in Ib2 (1,000 U/ml recombinant human IL-2; a gift from P. Kar- 
nani,  Orion-Farmos,  Turku,  Finland) containing  RPMI  1640 
medium that was supplemented with 4 mM t-glutamine, 10 mM 
Hepes, 100 U/ml penicillin, 100 ~g/ml streptomycin,  20% human 
AB-serum, and 1 #g/ml PHA for 4 wk at 37~  in 5% CO2. 
Antibodies.  Antibodies  used in this study are listed in Table 1. 
mAb HP 2/1 recognizes the ~4 chain of very late activation an- 
tigen 4 (VLA-4) (34), and it does not cross-react with the c~ chain 
of intraepitheial lymphocyte integrin (c~IEL) (Butcher, E., unpub- 
lished observations), mAb HMbl against oriEL/B7 recognizes ei- 
ther a combinatorial epitope composed of both chains of this inte- 
grin or an epitope that is conformation specific  (35). Anti-mouse 
/57 mAbs were produced by immunizing rats with TK1 cells and 
screened for their ability to block TK1 cell aggregation induced 
by an activating anti-B7 mAb LS722. The three Fib mAbs recog- 
nize nonoverlapping epitopes in B7 chain, and they all inhibit cell 
adhesion to VCAM-1, fibronectin, MAdCAM-1, and intestinal ep- 
ithelium and they block lymphocyte  homing to Peyer's  patches (36). 
In the present study we show that these antibodies also cross-react 
with functionally  relevant epitopes  of human B7. A polyclonal  rabbit 
antiserum and a rat mAb AIIB2 (37) against B1 were used with 
similar results, mAb SR 84 against cd (38) inhibits binding to 
laminin and to coUagens I, IV, and V (Heino, J., unpublished ob- 
servations), mAbs AIIB2 and SK 84 were purified  from asdtes using 
protein G-Sepharose columns. Leu-8 and Dreg-56 against bselectin 
gave identical staining results, and in  HEV-binding assays the 
function-inhibiting Dreg-56 was used (39). All mAbs were used 
as purified Ig or as serum-free cell culture supernatants. All anti- 
bodies, except Leu-8, are against functional epitopes. 
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using an in vitro frozen section assay  (41). Normal appendices were 
obtained from elective appendectomies, inflamed synovial mem- 
branes from synovectomies  (rheumatoid arthritis patients), and pe- 
ripheral lymph nodes from surgical explorations performed for di- 
agnosis of lymphadenopathy  (only nonmalignant nodes were used). 
Alternatively, mouse peripheral lymph nodes and Peyer's patches 
were used in these assays.  It has been previously  shown that binding 
of  cells to HEV in corresponding human and mouse tissues  is com- 
parable (33, 42). 8-/~m frozen sections from tissues were freshly 
cut, and overlaid with 3  x  106 LPL suspended  in RPMI 1640 sup- 
plemented with 5% AB-serum and 10 mM Hepes, pH 7.2. Under 
constant rotation, lymphocytes  were allowed  to bind to endothelial 
cells in the sections for 30 min at  + 7~  Thereafter, the nonad- 
herent cells  were gently tilted off, and the adherent cells were fixed 
to the sections overnight in ice-cold  PBS containing 1% glutaralde- 
hyde. At least 4 sections and 100 HEV per sample were analyzed 
under dark-field illumination. Adherence of small and large lym- 
phocytes was counted separately. Large lymphocytes were defined 
as cells with a diameter at least 1.3 times (and two-dimensional 
surface area i>1.75 times) that of small lymphocytes. The propor- 
tion of large cells was counted microscopically  in each sample be- 
fore the HEV assay,  and it was 5% on average. The same percentage 
was obtained from fluorescence-activated  cell sorting analyses  (see 
below). The few monocytes that remained in the starting popula- 
tion occasionally  adhered to HEV, but were easily  identified  by their 
large diameter and raffled appearance and excluded from the anal- 
yses. Binding of LPL from separate experiments was normalized 
by using PBL in each experiment as controls. The results are ex- 
pressed as relative  adherence ratios (RAIL) where RAIL 1.0 defines 
the adherence of PBL. Thus, for LPL RAIL value 1.0 means that 
they bind as well as PBL, ILAIL  values >1.0 mean that they bind 
better than PBL, and RAIL values <1.0 mean that they bind less 
efficiently than PBL to the endothelium studied. In preliminary 
assays, we ruled out the possible effects of collagenase treatment 
on HEV-binding by showing that fresh PBL and PBL coprocessed 
with lamina  propria cells had no significant  differences  in their HEV- 
binding properties. 
For inhibition assays, a mucosal T cell line was initially used 
because of the high number of immunoblasts needed (3  x  106 
blasts/tissue section, six sections/antibody,  five  inhibitory antibodies 
plus controls, and two target tissues). The phenotypical and func- 
tional properties of this T cell line that justify its use are shown 
in Results. Cells were first treated with saturating concentrations 
of  inhibitory rat mAbs against 37, inhibitory mouse mAbs against 
human CD18, VLA-4ot,  CD44,  and negative controls (3G6, a 
mouse mAb, and 281.2, a rat mAb) for 30 min at 4~  Similarly, 
polyclonal rabbit antiserum against 31 and normal rabbit serum 
as control were employed  in the inhibition assays. Thereafter, cells 
were applied onto synovial and mucosal (human appendix) tissue 
sections (without washing away the antibodies), and the HEV- 
binding assay was then carried out as described above. Counting 
of the cells adherent to HEV was done from coded samples in a 
single blinded manner. The results are expressed as percentage of 
maximal binding where binding of cells in the presence of the ap- 
propriate negative  control (mAb 3G6, 281.2 or normal rabbit serum) 
defines 100% binding. 
To confirm the HEV-binding results with freshly isolated ceils, 
LPL from normal bowels were isolated, treated with inhibitory 
mAbs, and applied onto the tissue sections (human appendix and 
synovium). In these experiments, mAbs HML-1 against c~IEL/~7, 
Dreg-56 against L-selectin, AIIB2 against B1, and SIL 84 against 
al were included. Also, a control mAb against a monomorphic 
determinant on HLA-A,B,C  was used to rule out nonspedfic effects 
of  cell-bound mAbs on HEV adherence. In these experiments, only 
106 cells/section  and four sections per tissue type could be analyzed 
because of the limitations of the starting material. Binding of small 
and large LPL were counted separately as described above. 
FACS  |  Analyses.  Ceils  were stained for immunofluorescence 
using a two-step procedure as described earlier (28). Briefly, 0.5 
x  106 cells were incubated with the first-stage mAbs for 20 min 
at 4~  After washings in PBS containing 2% FCS and 1 mM 
sodium azide, appropriate FITC-conjugated  second-stage  antibodies 
were added for 20 min. Thereafter, cells were washed, fixed  in PBS 
containing 1% formaldehyde,  and analyzed  by a FACScan  |  cytom- 
eter (Becton Dickinson & Co., Mountain View, CA). Gates for 
small lymphocytes and large immunoblasts were defined on the 
basis of  the characteristic  light scatter  patterns and absence of  CD14, 
as described (31). Routinely, 10,000 events from each sample were 
collected, and for blasts ,,o5,000 events  were also separately  acquired 
using live gating. 
Results 
Mucosal Immunoblasts Bind to Synovial HEV.  LPL were en- 
zymatically  isolated from eight normal bowel specimens, and 
their adherence to three distinct endothelial specificities was 
studied using an in vitro HEV-binding assay (Fig. 1). Small 
lymphocytes from normal gut bound almost equally well to 
both mucosal and synovial HEV, but less efficiently to pe- 
ripheral lymph node HEV. Immunoblasts from normal gut 
bound approximately five times better to mucosal HEV than 
did small lymphocytes. Mucosal immunoblasts also exhibited 
a remarkable capacity to bind to synovial HEV.  In fact, gut 
immunoblasts adhered almost as efficiently to synovial HEV 
(RAK 4.9) as to mucosal HEV (PAR 5.0).  An example of 
gut immunoblasts interacting with synovial endothelium is 
shown in Fig. 2. In contrast, no mucosal immunoblasts ad- 
hered to normal peripheral lymph node HEV (Fig. 1). Thus, 
normal mucosal immunoblasts can interact with endothelium 
in mucosa and synovium, but not in peripheral lymph nodes. 
Characterization of  Functional mAbs against Human fl7.  Since 
87 plays a critical role in mucosal homing in mouse (13, 16), 
it was essential to include this integrin in the functional assays. 
As shown in Fig.  3 A, each of three different rat mAbs to 
mouse/~7 (Fib 21, 27,  and 504)  cross-reacted  with human 
PBL. The expression level is in concordance with recent reports 
showing that resting B ceils and a subpopulation of T cells 
in peripheral blood express/~7 (43,  44).  In mouse all these 
anti-~7 mAbs detect nonoverlapping epitopes,  yet they all 
inhibit mouse lymph node cell and human PBL binding to 
mouse MAdCAM-1 (36). To ascertain that these mAbs also 
block lymphocyte--endothelial cell interaction in humans, HEV 
assays were performed. As shown in Fig. 3 B, all three mAbs 
effectively inhibited human PBL binding to human appendix 
HEV. 
Freshly Isolated  and IL-2-dependent Mucosal Immunoblasts Dis- 
play Similar Adhesive Properties.  Since it is extremely difficult 
to isolate sufficient numbers of lamina propria immunoblasts 
from clinical specimens, we generated IL-2-dependent T cell 
lines from LPL to be used in the initial inhibition experi- 
ments. The validity of this approach is based on the following 
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Antibody 
Name  Type  Antigen  Source 
HP 2/1  Mouse IgG1 
Fib 21  Rat IgG2a 
Fib 27  Rat IgG2a 
Fib 504  Rat IgG2a 
B1  Polyclonal rabbit 
AIIB2  Rat IgG 
SR 84  Mouse IgG 
Leu-8  Mouse IgG2a 
Dreg-56  Mouse IgG2a 
Hermes-3  Mouse IgG2a 
TS  1/18  Mouse IgG1 
TS  1/22  Mouse IgG1 
HML-1  Mouse IgG2a 
W6/32  Mouse IgG2a 
3G6  Mouse IgG1 
281.2  Rat IgG2a 
cr 
37 
37 
37 
31 
c~1 
L-selectin 
L-selectin 
CD44 
CD18 
CDlla 
oeIEL 
HLA A,B,C 
Chicken  T cells 
Mouse syndecan 
*(Ref. 34) 
*(Ref. 36) 
*(Ref. 36) 
~(Ref. 36) 
s 
ll(Ref. 37) 
S(Ref. 38) 
*(Ref. 39) 
*(Ref. 24) 
**(Ref. 40) 
**(Ref. 40) 
*(Ref. 46) 
* Immunotech (Marseille, France). 
* Made in our laboratory. 
S Gift from Dr. J. Heino (MediCity Research Laboratory, Turku, Finland). 
IP Gift from Dr. C. Damsky (University of California at San Francisco). 
I Becton Dickinson & Co. 
** American Type Culture Collection (RockviUe, MD). 
* * Gift from Professor M. Jalkanen (Centre of Biotechnology, Turku, Finland). 
observations. First, approximately 2/3 of mucosal immuno- 
blasts are T cells (28, 45). Second, the expression profiles of 
homing-associated molecules on freshly isolated mucosal im- 
munoblasts  and IL-2-dependent  mucosal T  cell lines  were 
comparable.  When analyzed by flow cytometry, both cell types 
were shown to be oL4 + , 31 + , 37 + , CD18 + ,  CD44 + , and 
L-selectin-,  although some quantitative differences in the in- 
tensity of staining did occur (Fig. 4). Third, IL-2-dependent 
T  cells originated from the gut bind well to both mucosal 
and synovial HEV, but poorly to peripheral lymph node HEV 
(33), and hence fresh mucosal immunoblasts and mucosal T 
cell lines seem to be also functionally similar.  The selective 
HEV-binding pattern was also confirmed with the cell line 
used in the present study (Fig.  5). Although in quantitative 
terms,  the ceils of the T  cell line bound to a lesser extent 
than freshly isolated immunoblasts to all endothelial recog- 
nition specificities,  the gut-derived T  cell line displayed ex- 
actly the same HEV-binding selectivity (i.e., mucosal =  sy- 
novial  >>  peripheral)  as  freshly  isolated  mucosal  blasts. 
Moreover, binding of the gut-derived T cell line to synovial 
HEV was shown not to be nonspecifically due to the inflam- 
matory status of the target tissue,  since these ceUs did not 
bind to any considerable extent even to severely inflamed pe- 
ripheral nodes (Fig.  5). In this experiment, endothelial cells 
in the normal peripheral  node lacked E-selectin and VCAM-1, 
and contained only very low levels of intercellular adhesion 
molecule 1 (all three molecules are induced in endothelium 
during inflammation),  whereas the inflamed node displayed 
the hallmarks  of severe lymphadenitis (data not shown). Thus, 
IL-2-dependent mucosal T cell lines dosely resemble freshly 
isolated lamina propria immunoblasts,  both phenotypically 
and functionally. 
Mucosal T  Cell Line Binds to Mucosal HEV via f17.  Inhi- 
bition HEV assays were performed to analyze the contribu- 
tion of different homing receptors in mediating the binding 
of gut-derived T immunoblasts to mucosal HEV. The binding 
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Figure 1.  Mucosal  immunoblasts  bind to synovial  HEV. Small  and large 
(Blasts)  LPL were  freshly  isolated  from normal  human  gut and their binding 
to different  endothelium  specificities  (PLN, Peripheral  lymph  node;  GUT, 
appendix/Peyer's  patches; and 8YNOVIUM) was analyzed  using the in 
vitro frozen section  assay. Results from eight specimens  are expressed  as 
RAR  +  SEM (see Materials and Methods). Binding of control PBL 
(defining RAR 1.0) is indicated by the dashed line. 
of the mucosal T  cell line to mucosal HEV was inhibited 
by 80% by a pretreatment with an anti-o~4 antibody (Fig. 
6 A). Since oe4 can associate with either 81 or 87, cells were 
also separately preincubated with antibodies against each 8 
chain. These assays revealed that anti-81 treatment had only 
marginal inhibitory effect, whereas anti-fl7 mAb abrogated 
80% of binding. Anti-CD44 mAb treatment also dramati- 
cally inhibited binding (66%), but anti-LFA-1 mAb dimin- 
ished the adherence only by 26% (Fig. 6). L-selectin cannot 
play any role in this interaction since it is absent from the 
mucosal T  cell line (Fig.  4).  Thus, o,4/87 is the principal 
homing receptor directing binding of human gut-derived T 
cells to mucosal HEV. 
Mucosa-derived T Cell Line Uses  ol4/~1, CD44, and LFA-1 
in Binding to SynoviaIHEV.  To compare the usage of homing- 
associated molecules in binding to mucosal and synovial HEV, 
inhibition HEV assays were performed in which inflamed 
synovium was used as a target tissue (Fig. 6 B). Anti-VLA- 
4c~ mAb inhibited 28%  of binding of the mucosa-derived 
T  cell line to synovial HEV.  The contribution of different 
8  chains in the adherence to synovium was completely dis- 
tinct from that in mucosal binding: anti-81 antibody prevented 
m25%  of binding, whereas anti-87 had only marginal, if 
any, effect. CD44 appeared to be the most important single 
adhesion molecule involved in binding of mucosal T cell line 
to synovium, since anti-CD44 mAb (Hermes-3)  abrogated al- 
most 40% of binding. Anti-CD18 prevented m20% of ad- 
herence to synovial HEV (Fig.  6 B). These results indicate 
that CD44, VLA-4, and LFA-1 all contribute to binding of 
mucosal blasts to synovial HEV, but that ot4/87 is not used 
in this interaction. 
Binding of  Freshly Isolated  Mucosal LPL to Mucosal and Sy- 
novial HEV.  Since some differences did exist between cul- 
tured IL-2-activated T cells and freshly isolated LPL in the 
Figure 2.  Small and large LPL interact with endothelial  cells in the 
synovium. A dark-field  micrograph  illustrates  binding of three mucosal 
immunoblasts (white arrows) and three small lymphocytes  (black arrows) 
to a synovial  HEV. The vessel is delineated  by the dark-appearing  base- 
ment membrane. Original magnification  at 160. 
expression  of adhesion molecules and in absolute binding 
efficiencies, we wanted to confirm the binding results with 
freshly isolated LPL. Freshly isolated mucosal immunoblasts 
also employed ot4/fl7  as the principal homing receptor for 
binding to mucosal endothelium, since mAbs against both 
subunits of this integrin diminished the binding by m75% 
(Fig. 7 A). ot4/fll (VLA-4) was not involved in this interac- 
tion, since an anti-81 mAb had no effect on the HEV binding. 
Moreover, oriEL/87, an integrin characteristic to intraepithelial 
T  cells and also expressed on a subpopulation of LPL (46) 
did not mediate adherence of mucosal immunoblasts to mu- 
cosal HEV, because immunoblasts preincubated with an anti- 
oriEL mAb bound to HEV as well as mock-treated cells. CD44 
and LFA-1 contributed significantly  to the mucosal HEV 
binding. L-selectin,  which is expressed at a very low level 
on freshly isolated blasts, has no significant effect on mucosal 
HEV binding in this assay system (Fig. 7 A). Thus, binding 
of freshly isolated mucosal immunoblasts to mucosal HEV 
closely resembles that of the mucosal T cell line, and is mainly 
mediated by o~4/87 integrin. 
Contribution of oe4-containing  integrins to synovial  binding 
of freshly isolated mucosal immunoblasts was less than to 
synovial adherence of the mucosal T  cell line (Fig.  7 B).  In 
all three independent assays, anti-81 caused slightly more in- 
hibition than anti-87. Anti-CD44 preincubation abrogated 
>50% of synovial binding and anti-CD18 treatment also in- 
hibited binding by 20%.  L-selectin  and oriEL~87 did not 
contribute to synovial binding of mucosal immunoblasts, or1 
which has been found at elevated levels on synovial fluid lym- 
phocytes of rheumatoid arthritis patients (47) did not play 
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Figure 3.  Characterization of anti-B7 mAbs. (.4) Cross-reactivity of three rat anti-mouse  B7 mAbs with human B7. Human PBL were stained 
for immunofluorescence with Fib 21, 27, 504, and a pool (all three Fibs together) and analyzed using a FACS  |  x-axis is the fluorescence intensity 
in a log-scale and y-axis is the relative number of cells. (B) Anti-mouse  ~7 mAbs inhibit human PBL binding to mucosal endothelium. PBL were 
preincubated with different anti-B7 mAbs and thereafter applied onto frozen sections of human appendices, and the bound cells were counted. Results 
(mean _+ SEM of two experiments) are shown as a percentage of maximal binding that is defined as the number of bound cells in a negative control 
antibody (mAb 281.2) treated samples. 
a role in synovial binding.  These data indicate  that freshly 
isolated mucosal immunoblasts and the T  cell line use analo- 
gous mechanisms to bind to synovial HEV. CD44 seems to 
be the only adhesion  molecule  studied  that  is significantly 
involved in this adherence (Fig.  7 B), but this interaction is 
apparently largely mediated by other, currently unknown mol- 
ecules  (see Discussion). 
From  these same experiments  we also evaluated binding 
of freshly isolated small LPL to mucosal and synovial HEV 
(Fig. 8). In general, small LPL used the same adhesion mole- 
cules as immunoblasts  for HEV binding.  Thus, binding  to 
mucosal HEV was mainly supported by ot4/37 (Fig.  8 A), 
and involvement of CD44 and VLA-4 was observed in binding 
to  synovial HEV  (Fig.  8  B). 
Discussion 
In the present work,  the binding of human gut lympho- 
cytes to vascular endothelium was analyzed to study the recir- 
culation pathways of mucosal cells. By using freshly isolated 
lamina propria immunoblasts and an IL-2-activated mucosal 
T  cell line  we found  that  mucosal immunoblasts  bind  ex- 
tremely well to mucosal endothelium,  but not at all to pe- 
ripheral lymph node HEV. Moreover, we showed that blast 
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Figure 5.  Mucosa-derived  T cell line  binds to mucosal  and synovial  HEV, 
but not to peripheral lymph node HEV. IL-2-activated  T cells were ap- 
plied onto sections of noninflamed human appendices, inflamed synovial 
membranes, noninflamed  peripheral lymph nodes and inflamed peripheral 
nodes. Binding to HEV was analyzed  and compared with that of normal 
PBL (used as a control). Binding of PBL to each tissue types defines the 
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Figure 4.  Expression  of homing-associated  mol- 
ecules on mucosal lymphocytes.  The IL-2-activated 
mucosal T-cell  line (11_,2  line), freshly  isolated small 
LPL (fresh  sinai/), and freshly  isolated lamina propria 
immunoblasts (fresh blasts) were stained for im- 
munofluorescence  and analyzed  using a FACScan  | 
(.4) Regions used to define small LPL (RI) and 
immunoblasts (R2) in freshly  isolated samples. (B) 
Histograms  showing the  adhesion molecule 
profiles, x-axis is the fluorescence intensity on a 
log scale, and 7-axis is the relative number of  cells. 
Mean fluorescence  intensities are given  in the upper 
right corner of  each pand. With all these cell types 
staining with anti-CDlla  and anti-CD18 mAbs 
gave identical histograms. (3G6) A negative con- 
trol (mAb 281.2 and normal rabbit serum gave 
comparable histograms). 
cells  from normal human gut have an inherent  capacity to 
interact efficiently with synovial HEV. We also dissected the 
molecular  mechanisms  that  regulate  this  dual  endothelial 
binding  of mucosal immunoblasts. 
Binding of mucosal immunoblasts to mucosal HEV was 
mediated by o~4/fl7  and,  to a lesser extent,  by CD44  and 
CD18.  The tissue specificity of this interaction is probably 
conferred in large part by ol4/37,  because CD44 and CD18 
are involved in HEV binding in a nontissue-specific fashion 
(see below). Since pretreatment with both anti-oL4 and anti- 
37 mAbs yielded virtually indistinguishable inhibition per- 
RAR-value 1.0. Results from two independent assays  are expressed as PAR 
+_ SEM. Note that the inflammatory status of peripheral nodes has only 
marginal effects on the efficacy  of mucosal T cell line adherence. 
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Figure  6.  c~4/#7 is the principal integrin mediating 
binding of mucosal T  cell line to mucosal HEV whereas 
VLA-4, CD44,  and LFA-1 all contribute to the binding 
to synovial HEV. Ib2-activated mucosal T cells were prein- 
cubated with inhibitory antibodies against ce4, B1,  87, 
CD44, CD18, or with negative controls (3G6, 281.2, and 
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inflamed synovium was analyzed.  Results of two inde- 
pendent experiments are expressed as a percentage of max- 
imal binding _+ SEM, in which the number of adherent 
cells in the presence of" the appropriate negative control 
antibody defines 100% binding. 
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Figure  7.  Binding  of freshly isolated  immunoblasts 
from normal bowel to HEV, Binding of freshly isolated 
gut immunoblasts to (A) mucosal HEV (human appendix) 
and (B) synovial HEV is shown. Inhibition HEV assays 
were performed exactly as described in the legend for Fig. 
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vant binding anti-HLA-ABC mAb was used as a control 
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~1, and L-selectin were included. Results are from three 
independent experiments (LPL from different individuals) 
and are presented as mean  _+  SEM. A 
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Figure  8.  Binding of freshly isolated smaU LPL 
from normal bowel to HEV. Binding of freshly iso- 
lated gut LPL to (.4) mucosal HEV and to (/3) syno- 
vial HEV was analyzed. These data are derived from 
the same experiments as shown in Fig. 7, but binding 
of small LPL was counted. 
centages, and anti-~l had no significant effect, all the func- 
tionally active o~4 that mediates adherence to mucosal HEV 
is in the form of ol4/~7. Theoretically, it is also possible that 
anti-fl7 mAbs send a negative signal to the cell, which turns 
offother mucosa-specific adhesion systems. In mouse, ol4/~7 
has been shown to be the principal homing receptor that directs 
binding of mesenteric lymph node lymphocytes and lymphoid 
cell lines to gut-associated lymphatic tissues in vitro and in 
vivo (12, 13, 16, 48). Our findings extend these observations 
to mucosal effector cells of lamina propria, and for the first 
time show that ol4/B7 plays a critical role in mucosal homing 
in humans. 
B7 can also be associated with ozlEL (35, 49).  o~IEL/~7 
heterodimer has been reported to be expressed in intraepithelial 
lymphocytes of gut, and it mediates binding of this lympho- 
cyte subpopulation to epithelial cells (50). o~IEL  is also present 
on a subpopulation of LPL (46). However, our HEV-binding 
experiments revealed  that  cdEL/B7  expressed  on lamina 
propria  immunoblasts  did  not  participate  in  endothelial 
binding (actually, odEL/~7 is not a receptor for MAdCAM-1, 
Butcher, E. C., unpublished data). Although integrins may 
not function maximally at 7~  anti-LFA-1 and anti-37 mAbs 
do dearly inhibit binding in HEV assays (12, 16, 25, 26, and 
our present results).  A possibility remains, of course,  that 
all the functions of oriEL integrin may not be completely 
blocked by HML-1 mAb. However, in the currently employed 
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binding assays, only pairing of 37 with or4 yields a function- 
ally active mucosal homing receptor. 
In contrast, ~7 was not involved to any significant extent 
in the binding of human mucosal immunoblasts to synovial 
HEV. It is interesting to note that the other ol4-containing 
integrin, o~4/~1 (VLA-4), contributes to synovial adherence 
of the mucosal T cell line and freshly isolated mucosal im- 
munoblasts. Thus, the two different a4-containing integrins 
are differentially  used in the binding of mucosal immuno- 
blasts to mucosal and synovial HEV. However, VLA-4 cannot 
explain the tissue specificity of synovial HEV binding, be- 
cause it played only a relative minor role in binding and it 
mediates adhesion of lymphocytes in several endothelial rec- 
ognition systems (51-53). 
mAb Hermes-3 to CD44 significantly  inhibited binding 
of mucosal lymphocytes to both mucosal and synovial HEV. 
Earlier, CD44 has been shown to be involved in PBL binding 
to HEV in gut-associated lymphatic tissues, peripheral lymph 
nodes, and synovium (24). However, mAb Hermes-3 against 
CD44 only inhibited binding of PBL to mucosal HEV, but 
not to synovial HEV (24). Thus, mucosal lymphocytes and 
nonactivated  PBL  can  apparently  use  CD44  differently 
(different epitopes, signaling events, and/or activation stage) 
when binding to synovial HEV. Moreover, recent data sug- 
gest that in lymphocyte adhesion to HEV, CD44 may func- 
tion as a facilitating molecule rather than a specificity con- ferrer (16). Thus,  on mucosal LPL both CD44 and LFA-1 
apparently function as nontissue-specific adhesion molecules. 
Small LPL expressed most adhesion molecules at lower level 
than immunoblasts.  However, small lymphocytes basically 
used the same homing receptors as immunoblasts in HEV 
binding.  Thus,  binding  to mucosa took place mainly via 
o~4/1~7, whereas CD44 and VLA-4 conferred adherence to 
synovial vessels. However, CD18 only played a very minor 
role in binding of small LPL to synovium. Overall, rather 
similar use of adhesion molecules by small LPL and immu- 
noblasts most likely reflects the fact that most small LPL in 
gut are memory-type cells (45) that have same kind of recir- 
culation pathways as immunoblasts (1). 
The  currently known  homing-associated  molecules  of 
mucosal lymphocytes do not fully account for the synovial 
adherence, especially  if CD44 mainly functions as an acti- 
vator of other adhesion receptors. Also in other studies, only 
partial inhibition of PBL and monocyte and synovial lym- 
phocyte binding to synovial endothelium by mAbs against 
CD44, L-selectin, VLA-4, and LFA-1 has been reported (51, 
54-56). Thus, novel homing molecules may remain to be dis- 
covered that mediate binding of different lymphocytes to sy- 
novial HEV. Alternatively, the specificity of synovial binding 
may be conferred by a unique combination of sequential adhe- 
sion and activation steps  (7,  10). 
The critical role of c~4/~7 in mucosal HEV binding indi- 
cates  that  it  uses  MAdCAM-1,  a  mucosal addressin,  as  a 
counter-receptor. Although c~4/fl7 can also bind to VCAM-1 
and fibronectin (16, 57,  58),  only MAdCAM-1 can confer 
the organ specificity of binding, since fibronectin is nonspe- 
cifically absorbed to the surface of all cells of vascular lining, 
and VCAM-1 is not present to any significant extent in ei- 
ther normal or inflamed mucosa (31, 59). In mouse, the im- 
portance of ot4/~87 interaction with MAdCAM-1 has been 
directly proven (16) and our current studies suggest that similar 
molecular mechanisms are used in humans although the human 
homologue of MAdCAM-1 remains to be found. On the other 
hand, involvement of VLA-4 in the binding of mucosal im- 
munoblasts to synovial HEV strongly suggests that VCAM-1 
will be its principal counterpart in synovial endothelium (18). 
VCAM-1 was, in fact, moderately expressed in the vessels 
of the synovial membranes used in the present HEV-binding 
assays, and also in other studies it has been shown to be present 
in the inflamed synovium (60, 61). Furthermore, our results 
indirectly indicate that in synovial venules VCAM-1 is not 
a physiologically significant ligand for ~4/~7 of the mucosal 
T  cell line. 
Earlier animal studies have suggested that mucosal immu- 
noblasts specifically  home back to mucosa-associated lym- 
phatic tissues.  In their classical work, Gowans and Knight 
(62) showed that small lymphocytes isolated from the rat tho- 
racic duct rapidly homed to all lymphoid tissues  when in- 
jected into syngeneic animals. In contrast, large lymphocytes, 
which presumably consisted mainly of activated mucosal blasts, 
preferentially localized in the lymphoid tissues  of the gut, 
and practically none were found at other locations. Selective 
migration of immunoblasts from mesenteric nodes and lymph 
back into mucosa-associated lymphatic tissues has been con- 
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firmed in later reports (63-66). However, our results for the 
first time elucidate the interactions of lamina propria immu- 
noblasts with endothelium, and provide the molecular ex- 
planation for these interactions in humans. Moreover, a pre- 
viously unknown interaction between mucosal immunoblasts 
and synovial HEV was found. Based on our HEV-binding 
data, we propose a putative model of mucosal immunoblast 
interaction with endothelial cells in gut, synovium, and pe- 
ripheral lymph node (Fig.  9). 
Several observations indicate that synovial HEV binding 
of mucosal immunoblasts is not merely due to the inflamma- 
tory status of the target tissue. Mucosal immunoblasts from 
the T cell line did not bind to human peripheral lymph nodes 
that  are severely inflamed any better than to noninflamed 
lymph nodes, although endothelial ligands ofa4/fll, CD44, 
and LFA-1 are expressed both in the inflamed synovium and 
lymph node. Moveover, IL-2-activated T cell lines originated 
from peripheral lymph nodes and most of those generated 
from PBL show only marginal binding to inflamed synovial 
HEV (33). Finally, IL-2-propagated tumor infiltrating lym- 
phocytes that adhere efficiently  to the tumor vasculature, show 
negligible binding to HEV in the inflamed synovium (Salmi, 
M., and S. Jalkanen, manuscript submitted for publication). 
Together, these data suggest that mucosal immunoblasts have 
some unique properties (e.g., response to activation factors 
in the second step of adhesion cascade;  7,  10)  that render 
them capable of dual binding. It is of interest to note, how- 
ever, that chronic inflammation of the gut alters the HEV- 
binding specificity of mucosal immunoblasts. Thus, immu- 
noblasts from ulcerative colitis and Crohn's disease bowels 
bind to normal peripheral nodes, and this binding is medi- 
ated by interaction of peripheral lymph node addressin with 
a currently unknown, non-L-selectin ligand (31). 
The present findings suggest that the normal lamina propria 
contains immunoblasts that are able to home either to the 
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Figure  9.  Schematic  model  ofmucosal  immunoblast  interactions  with 
different  endothelial  recognition  specificities  in humans. Mucosal  immu- 
noblasts express ~4//~1, ~4/~7, LFA-1, and CD44, but not bselectin. 
The putative interactions  with endothelial  ligands in mucosal  lymphatic 
tissues, synovium  and peripheral lymph nodes are illustrated. The thick- 
ness of the line connecting  the lymphocyte  adhesion receptor  and its en- 
dothelial cell ligand is proportional to the importance  of each receptor- 
ligand pair in recognition  of  distinct endothelial  cell  specificities  as revealed 
in our current in vitro model. 
to Synovium mucosa or to the synovium. This may explain the develop- 
ment of extraintestinal manifestations not uncommonly en- 
countered in the infectious and inflammatory bowel diseases 
(29, 30).  In the case of arthritis,  the following hypothesis 
may be put forth:  after recognizing  their cognate antigen 
at mucosal sites,  activated immunoblasts will return to the 
blood circulation. Thereafter, blast cells can home either back 
to mucosal sites or alternately to synovium. Accumulation 
of antigen-specific blasts in joints would result in aggrava- 
tion of synovitis, especially if the triggering antigen is trapped 
at  synovial sites  (67). 
In conclusion, we have shown here that mucosal immu- 
noblasts have a dual endothelial binding capacity- they bind 
both to mucosal and synovial HEV, but not to peripheral 
lymph nodes. Binding of mucosal blasts to gut-associated lym- 
phatic tissues is mainly mediated by o~4//~7. In contrast, the 
same cells utilize different, mostly yet-to-be-described adhe- 
sion molecules in adherence to synovial sites.  This kind of 
elucidation  of the  molecular  mechanisms  of lymphocyte- 
endothelial interactions between mucosal immunoblasts and 
inflamed synovium may in the future be helpful in designing 
new methods to alleviate joint complications connected to 
inflammatory  and infectious bowel diseases. 
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